We are pleased to share additional data from our Phase 2b NAVIGATE study at ID Week which further validates CD388 as a potential once per season influenza preventative option,” said Jeffrey Stein, Ph.
Moderna (MRNA) announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in ...
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, ...
JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's ...
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop ...
The clinic will be Oct. 15-17 from 9 a.m.-7 p.m. each day, according to a news release. The drive-thru will be at the Shannon South Campus in the parking lot on Executive Drive between the Shannon ...
MedPage Today on MSN
Don't Fear Oseltamivir in Kids Hospitalized With Flu
Kids who received oseltamivir during their flu-related hospitalization were 31% less likely to be admitted to the ICU ...
This season's influenza vaccine may have been a poor match to a strain of the flu virus that caused many infections this winter, early data released by the Centers for Disease Control and Prevention ...
With winter on the horizon, local health experts warn about a rise in respiratory illnesses. Dr. Tjaden emphasizes hygiene ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback